CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 136 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,510 | +43.8% | 5,668 | +5.6% | 0.00% | +33.3% |
| Q2 2023 | $58,780 | +208.2% | 5,368 | -12.5% | 0.00% | +200.0% |
| Q1 2022 | $19,071 | -73.9% | 6,132 | -69.4% | 0.00% | 0.0% |
| Q3 2021 | $73,150 | -28.1% | 20,041 | -10.5% | 0.00% | -50.0% |
| Q1 2021 | $101,710 | +66.9% | 22,403 | +111.1% | 0.00% | +100.0% |
| Q4 2020 | $60,924 | -43.4% | 10,614 | -28.6% | 0.00% | -50.0% |
| Q3 2020 | $107,666 | +28.2% | 14,871 | -38.2% | 0.00% | +100.0% |
| Q2 2020 | $84,015 | -20.3% | 24,073 | +16.9% | 0.00% | -50.0% |
| Q3 2019 | $105,467 | -26.0% | 20,599 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $142,484 | -46.1% | 19,900 | 0.0% | 0.00% | -60.0% |
| Q1 2019 | $264,272 | +68.7% | 19,900 | 0.0% | 0.01% | +66.7% |
| Q4 2018 | $156,613 | -29.0% | 19,900 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $220,492 | -99.9% | 19,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $267,058,000 | – | 19,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |